BioFlash: Jounce forges Celgene deal; What Juno bought from a Boston professor

​Cambridge’s Jounce announces $2.5B deal with Celgene for cancer drugs

The 3-year-old biotech has pulled off a deal that’s of a size usually reserved for much more advanced biotechs.

Why Shire is expecting its pending drug launch to be a blockbuster

The drugmaker is banking on is the fact that the straightforward labelling allowed by the FDA on its newly-approved eye drop, Xiidra, will help it overtake the competition.

​Here’s what Juno just bought for $10M plus milestones from a Boston professor

Michail “Misha” Sitkovsky, professor of immunophysiology and the director of New England Inflammation and Tissue Protection Institute, contends that Juno Therapeutics is getting a lot more than access to a single drug that can work in conjunction with immunotherapies.

​Third Rock goes solo with $55M for new rare genetic disease biotech

The Cambridge startup's name summarizes its mission to restore balance to the regulation of gene mutations that cause disease.

​Pulmatrix shares climb as generic Spiriva hits goals in early-stage trial

​Ziopharm calls patient death in drug trial ‘an isolated case,’ shares fall

DivcoWest makes a mint as Alexandria plans to expand One Kendall Square

Newton REIT capitalizes on low rates with $620M refi of Vertex headquarters

Boston Business Journal Science & Tech Newsletters

Subscribe to additional BBJ Newsletters in Science, Tech and Venture Capital

Connect with us